Notable Runners - Valeant Pharmaceuticals, (NYSE:VRX), Skyline Medical, (NASDAQ:SKLN)

Adjust Comment Print

For the Current Quarter, the growth estimate for Valeant Pharmaceuticals International, -35%, while for the Next Quarter the stock growth estimate is -17.6%.

When it comes to the Analysis of a Stock, Price Target plays a vital role.

Following previous ticker characteristics, Valeant Pharmaceuticals International, Inc. Rodman & Renshaw reiterated a "buy" rating and issued a $90.00 target price on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th.

After the last closing session, the bid price was seen at 20.19. 12 analysts have rated the company as a "Hold". The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned "Buy" rating by TD Securities on Thursday, August 11.

(NYSE:VRX) also run on active notice, stock price increased 1.86% after traded at $23.59 in most recent trading session. The company rocked its 52-Week High of $179.83 on Oct 16, 2015 and touched its 52-Week Low of $18.55 on Jun 27, 2016. The company's Market capitalization is $7.52 Billion with the total Outstanding Shares of 341.19 million. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of USA and worldwide copyright law. (NYSE:VRX) will issue their earnings release on or around 2016-10-17. Just prior to the release, analyst's estimates had a standard deviation of 0.26. "Valeant Pharmaceuticals International, headquartered in Mississauga, Canada". The business's revenue was down 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.14 earnings per share. They now have a United States dollars 46 price target on the stock. The company is expected to report its next EPS (earnings per share) on Nov 08 BMO. The stock negotiated total number of 9.87 million shares as compared to 3 months average volume of 23.4 million shares. Creative Planning now controls 200 shares valued at $0. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 16.37% of the company's stock.

Several equities analysts have recently issued reports on the company. While it's Return on Investment (ROI) value is 3.7%. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth approximately $1,728,000.

08/15/2016 - Valeant Pharmaceuticals International, Inc. was upgraded to "neutral" by analysts at Mizuho. In the last six months the stock's performance fell -30.69% while yearly performance of the company fell -86.80%.The company's year to date (YTD) performance is at -77.43%.

Valeant Pharmaceuticals International a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with's FREE daily email newsletter.